Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

By Sandi Wong, Assistant Editor
December 10, 2020 11:52 PM UTC
Updated on Dec 12, 2020 at 2:43 AM UTC
Editor's note: Story updated to reflect stock's close on Friday, Dec. 11.

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity.

Evelo Biosciences Inc. (NASDAQ:EVLO) has gained 44% to $7.54 since reporting the results Wednesday for lead program EDP1815 in mild-to-moderate atopic dermatitis. It’s the second indication in which Evelo has reported clinical efficacy for the program after psoriasis...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Evelo Biosciences Inc.